Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Accéder directement au contenu
Article Dans Une Revue Clinical Gastroenterology and Hepatology Année : 2023

Dates et versions

hal-03870157 , version 1 (24-11-2022)

Identifiants

Citer

Anthony Buisson, Maria Nachury, Mathurin Fumery. Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease. Clinical Gastroenterology and Hepatology, 2023, 21 (9), pp.2431-2432. ⟨10.1016/j.cgh.2022.11.006⟩. ⟨hal-03870157⟩
26 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More